Cardiff Oncology Stock Forecast, Price & News

-0.29 (-3.52 %)
(As of 06/15/2021 03:39 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume11,829 shs
Average Volume491,268 shs
Market Capitalization$298.90 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive CRDF News and Ratings via Email

Sign-up to receive the latest news and ratings for Cardiff Oncology and its competitors with MarketBeat's FREE daily newsletter.

Cardiff Oncology logo

About Cardiff Oncology

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops drugs for the treatment of cancer. Its lead drug candidate is onvansertib, a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor that is in Phase Ib/II clinical trial in acute myeloid leukemia (AML); has completed a Phase I clinical trial in advanced solid tumors; and Phase Ib/II clinical trial for metastatic colorectal cancer in combination with FOLFIRI and Avastin. The company's onvansertib is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer. In addition, it develops therapeutics, such as belinostat (Beleodaq); quizartinib (AC220), a development stage FLT3 inhibitor; and bortezomib (Velcade) for the treatment of leukemias, lymphomas, and solid tumor cancers. The company primarily serves pharmaceutical companies. Cardiff Oncology, Inc. has a research collaboration with Nektar Therapeutics for the treatment of colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2020. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.88 out of 5 stars

Medical Sector

133rd out of 2,100 stocks

Biological Products, Except Diagnostic Industry

19th out of 198 stocks

Analyst Opinion: 3.5Community Rank: 3.4Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Cardiff Oncology (NASDAQ:CRDF) Frequently Asked Questions

Is Cardiff Oncology a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cardiff Oncology in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Cardiff Oncology stock.
View analyst ratings for Cardiff Oncology
or view top-rated stocks.

What stocks does MarketBeat like better than Cardiff Oncology?

Wall Street analysts have given Cardiff Oncology a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Cardiff Oncology wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Cardiff Oncology's next earnings date?

Cardiff Oncology is scheduled to release its next quarterly earnings announcement on Tuesday, August 10th 2021.
View our earnings forecast for Cardiff Oncology

How were Cardiff Oncology's earnings last quarter?

Cardiff Oncology, Inc. (NASDAQ:CRDF) released its quarterly earnings results on Friday, May, 7th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.01. The company had revenue of $0.07 million for the quarter, compared to analysts' expectations of $0.08 million. Cardiff Oncology had a negative net margin of 5,512.97% and a negative trailing twelve-month return on equity of 26.25%.
View Cardiff Oncology's earnings history

What price target have analysts set for CRDF?

3 analysts have issued 1-year price targets for Cardiff Oncology's stock. Their forecasts range from $25.00 to $30.00. On average, they anticipate Cardiff Oncology's share price to reach $26.67 in the next twelve months. This suggests a possible upside of 235.0% from the stock's current price.
View analysts' price targets for Cardiff Oncology
or view top-rated stocks among Wall Street analysts.

Who are Cardiff Oncology's key executives?

Cardiff Oncology's management team includes the following people:
  • Dr. Mark Erlander, CEO & Director (Age 61, Pay $597.33k)
  • Ms. Brigitte Lindsay, VP of Fin.
  • Ms. Vicki Kelemen, Exec. VP & COO
  • Ms. Elizabeth Anderson, VP of Fin. & Admin.

Who are some of Cardiff Oncology's key competitors?

What other stocks do shareholders of Cardiff Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cardiff Oncology investors own include Sorrento Therapeutics (SRNE), Livongo Health (LVGO), Co-Diagnostics (CODX), Novavax (NVAX), Fortress Biotech (FBIO), Maxar Technologies (MAXR), Ontrak (OTRK), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX) and Cassava Sciences (SAVA).

What is Cardiff Oncology's stock symbol?

Cardiff Oncology trades on the NASDAQ under the ticker symbol "CRDF."

Who are Cardiff Oncology's major shareholders?

Cardiff Oncology's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Janus Henderson Group PLC (7.82%), Corriente Advisors LLC (7.42%), Opaleye Management Inc. (1.53%), BlackRock Inc. (1.43%), Millennium Management LLC (0.86%) and Frazier Management LLC (0.78%). Company insiders that own Cardiff Oncology stock include Gary W Pace, John P Brancaccio, Mark Erlander, Rodney S Markin and Vicki Kelemen.
View institutional ownership trends for Cardiff Oncology

Which major investors are selling Cardiff Oncology stock?

CRDF stock was sold by a variety of institutional investors in the last quarter, including Opaleye Management Inc., Frazier Management LLC, Prospera Financial Services Inc, Citigroup Inc., and Bank of New York Mellon Corp.
View insider buying and selling activity for Cardiff Oncology
or view top insider-selling stocks.

Which major investors are buying Cardiff Oncology stock?

CRDF stock was bought by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Corriente Advisors LLC, Millennium Management LLC, HRT Financial LP, Kennedy Capital Management Inc., BlackRock Inc., Goldman Sachs Group Inc., and Virtu Financial LLC. Company insiders that have bought Cardiff Oncology stock in the last two years include Gary W Pace, John P Brancaccio, Mark Erlander, Rodney S Markin, and Vicki Kelemen.
View insider buying and selling activity for Cardiff Oncology
or or view top insider-buying stocks.

How do I buy shares of Cardiff Oncology?

Shares of CRDF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cardiff Oncology's stock price today?

One share of CRDF stock can currently be purchased for approximately $7.96.

How much money does Cardiff Oncology make?

Cardiff Oncology has a market capitalization of $298.90 million and generates $370,000.00 in revenue each year. The company earns $-19,310,000.00 in net income (profit) each year or ($1.08) on an earnings per share basis.

How many employees does Cardiff Oncology have?

Cardiff Oncology employs 11 workers across the globe.

What is Cardiff Oncology's official website?

The official website for Cardiff Oncology is

Where are Cardiff Oncology's headquarters?

Cardiff Oncology is headquartered at 11055 FLINTKOTE AVENUE, SAN DIEGO CA, 92121.

How can I contact Cardiff Oncology?

Cardiff Oncology's mailing address is 11055 FLINTKOTE AVENUE, SAN DIEGO CA, 92121. The company can be reached via phone at 858-952-7570 or via email at [email protected]

This page was last updated on 6/15/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.